EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Ramin Tadayoni, Laura Sararols, Georges Weissgerber, Rohini Verma, Andreas Clemens, Frank G Holz

Ophthalmologica · 2021 · 244 (2) · 93-101

DOI: 10.1159/000513048 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ophthalmologica, online erschienen am 16.11.2020. Verfasst von Ramin Tadayoni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Macular Degeneration. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD).

Purpose

To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans.

Methods

In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation.

Results

The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control.

Conclusions

The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsMacular DegenerationAntibodies, Monoclonal, HumanizedHumansIntravitreal Injections

Stichwörter der Autor:innen

Anti-VEGFBrolucizumabNeovascular age-related macular degeneration (AMD)Single-chain antibody fragment

Substanzen

Angiogenesis InhibitorsAntibodies, Monoclonal, Humanizedbrolucizumab

Autor:innen und Institutionen

  • Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France.
  • Hospital General de Catalunya, Barcelona, Spain.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharma AG, Basel, Switzerland, andreas.clemens@novartis.com.
  • Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, andreas.clemens@novartis.com.
  • Department of Ophthalmology, University of Bonn, Bonn, Germany.

Zitieren

APA

Tadayoni, R., Sararols, L., Weissgerber, G., Verma, R., Clemens, A., & Holz, F. G. (2021). Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 244(2), 93-101. https://doi.org/10.1159/000513048

Vancouver

Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. doi:10.1159/000513048

BibTeX
@article{Tadayoni2021,
  author = {Tadayoni, Ramin and Sararols, Laura and Weissgerber, Georges and Verma, Rohini and Clemens, Andreas and Holz, Frank G},
  title = {Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration},
  journal = {Ophthalmologica},
  year = {2021},
  volume = {244},
  number = {2},
  pages = {93--101},
  doi = {10.1159/000513048}
}
Kostenlos starten →